title: New immunotherapeutic strategies for the treatment of neuroblastoma.
abstract: The prognosis of high-risk neuroblastoma (NB) is still poor, in spite of aggressive multimodal treatment. Recently, adjuvant immunotherapy with anti-GD2 antibodies combined with IL-2 or GM-CSF has been shown to improve survival. Several other immunotherapy strategies proved efficacy in preclinical models of NB, including different types of vaccines, adoptive cell therapies and combined approaches. The remarkable differences in the immunobiology of syngeneic models and human NB may, at least in part, limit the translation of preclinical therapies to a clinical setting. Nonetheless, several preliminary evidences suggest that new antibodies, cancer vaccines and adoptive transfer of lymphocytes, genetically engineered to acquire NB specificity, may result in clinical benefit, and clinical studies are currently ongoing.
authors: IRCCS-A.O.U. San-Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Biotherapy Unit c/o CBA Torre C2, Largo R. Benzi 10, 16132 Genoa, Italy.
authors: Michela
authors: M
authors: Croce
authors: Maria Valeria
authors: MV
authors: Corrias
authors: Valentina
authors: V
authors: Rigo
authors: Silvano
authors: S
authors: Ferrini
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D019496:Cancer Vaccines; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D004353:Drug Evaluation, Preclinical; D005732:Gangliosides / Q000276:immunology; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000627:therapeutic use; D009447:Neuroblastoma / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D019496:Cancer Vaccines; D005732:Gangliosides; D007376:Interleukin-2; C019403:ganglioside, GD2; D016178:Granulocyte-Macrophage Colony-Stimulating Factor
keywords: NK cells; adoptive cell therapy; interleukin; monoclonal antibodies; neuroblastoma; vaccines